In order to promote human health through the highest quality, ethically-conducted clinical research, the Cross Cancer Institute provides a dedicated Clinical Trials Unit to ensure that the investigators have access to  high-quality research staff, infrastructure and administrative support to conduct cancer trials.

The CCI's Clinical Trial Unit (CTU) has a very active clinical trial program, providing state-of-the-art clinical care and equipment.  CCI's CTU aims to maintain 100-200 open studies available for patient enrollment and as of September 30, 2014, the CTU had accrued more than 5000 patients onto trials in all phases of investigation.  Funding for CTU core operations was made possible through a partnership between Alberta Cancer Foundation and CancerControl Alberta. 

CCI's CTU is led by Dr. John Mackey (Medical Director) and Ms. Leslie Fedorak (CTU Manager) and employs 32 CRNs and 29 CRCs to support industry-sponsored studies and co-operative group or academic clinical trials. Many of the front-end study activities are co-ordinated through their dedicated Trial Launch Team to help make the start up of trials as efficient as possible for sponsors and PIs.

CCI requires in-house regulatory and monitoring staff to monitor the scope of clinical-trial activities, including phase I studies and investigator-initiated studies conducted by the CCI CTU.


CTU Medical Director
Dr. John Mackey, MD FRCPC

As a medical oncology clinical investigator, Dr. Mackey's major interest is the study of new drug treatments for breast cancer. He is the medical leader of the Clinical Research Unit at The Cross Cancer Institute and is the co-chair of research for the Northern Alberta Breast Cancer Program. He is executive director of the Cancer International Research Group, Translational Cancer Research International, and serves on the steering committees of eleven international systemic therapy trials.

Dr. Mackey's translational research program focuses on the study of the molecular mechanisms underlying drug resistance, and explores novel ways to circumvent and modulate these resistance mechanisms. His research program is funded by the National Cancer Institute of Canada, the Alberta Cancer Board, the Alberta Cancer Foundation, the Alberta Chapter of the Canadian Breast Cancer Research Alliance, the Canadian Breast Cancer Research Alliance, the Department of Defense, and several industry sponsors.